Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are presently covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $13.97.
A number of research firms recently issued reports on VYGR. Canaccord Genuity Group decreased their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Citigroup initiated coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They set a "buy" rating and a $12.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th.
Check Out Our Latest Analysis on VYGR
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company's stock worth $18,232,000 after acquiring an additional 29,014 shares during the last quarter. Farallon Capital Management LLC grew its position in Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock worth $14,576,000 after purchasing an additional 278,700 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock valued at $7,828,000 after purchasing an additional 275,571 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Voyager Therapeutics by 151.0% in the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock worth $6,974,000 after buying an additional 740,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company's stock worth $6,149,000 after buying an additional 4,729 shares during the period. 48.03% of the stock is owned by institutional investors and hedge funds.
Voyager Therapeutics Price Performance
Shares of VYGR stock traded down $0.09 on Thursday, hitting $3.65. 277,697 shares of the stock traded hands, compared to its average volume of 466,170. Voyager Therapeutics has a 52 week low of $3.56 and a 52 week high of $10.66. The firm has a 50 day simple moving average of $4.51 and a two-hundred day simple moving average of $5.64. The firm has a market cap of $201.51 million, a price-to-earnings ratio of 5.14 and a beta of 0.99.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. During the same period in the prior year, the business earned $1.25 earnings per share. Sell-side analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current year.
About Voyager Therapeutics
(
Get Free ReportVoyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
